irbesartan
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
779
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
January 30, 2026
A Dual-Modal NIR-FLIM Probe for Hypothalamic Norepinephrine Imaging in Neurogenic Hypertension.
(PubMed, Anal Chem)
- "Critically, Angiotensin II type 1 receptor (AT1R) blockade (irbesartan, IRB) normalized NE levels and reversed vasculopathy. This work establishes a molecular platform linking hypothalamic NE dynamics to vascular pathology, enabling the mechanistic dissection of neurogenic hypertension and the quantitative evaluation of neuromodulation therapies."
Journal • Cardiovascular • Hypertension
January 10, 2026
PROPHYLACTIC IRBESARTAN THERAPY IN YOUNG PATIENTS WITH BICUSPID AORTOPATHY: AORTIC GROWTH RATES FROM A NEW ENGLAND COLLABORATIVE REGISTRY
(ACC 2026)
- "Abstract is embargoed at this time."
Clinical • Cardiovascular
January 26, 2026
A Review on Gamma-Oryzanol as a Multitarget Therapeutic Agent for Metabolic Syndrome: Mechanisms, Preclinical Evidence, and Clinical Prospects.
(PubMed, Curr Top Med Chem)
- "Compared to conventional therapies such as statins (LDL-C reduction: 30-50%) or antihypertensives (e.g., irbesartan), γ-ORY demonstrates milder efficacy but better tolerability, and may enhance the antihypertensive effects of irbesartan...However, the generalizability of current findings is limited by small sample sizes, inconsistent dosing regimens, and underrepresentation of diverse populations (e.g., various ethnic groups and pediatric cohorts). Large-scale, well-designed clinical trials are needed to validate its efficacy, optimize dosing, and assess long-term safety compared to standard therapies."
Journal • Preclinical • Cardiovascular • Diabetes • Dyslipidemia • Genetic Disorders • Hepatology • Hypertension • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Pediatrics • Type 2 Diabetes Mellitus
January 23, 2026
The Randomized Controlled Study of Shenqi Yishen Granules in the Treatment of IgA Nephropathy
(clinicaltrials.gov)
- P=N/A | N=102 | Not yet recruiting | Sponsor: Keda Lu
New trial • Glomerulonephritis • IgA Nephropathy • Renal Disease
January 09, 2026
STABILIZE-CKD: A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
(clinicaltrials.gov)
- P3 | N=1112 | Terminated | Sponsor: AstraZeneca | N=716 ➔ 1112
Enrollment change • Chronic Kidney Disease • Nephrology • Renal Disease
January 04, 2026
EVALUATING THE EFFECT OF SPARSENTAN VS IRBESARTAN ON URINE INFLAMMATORY AND PROFIBROTIC BIOMARKERS IN THE PHASE 3 PROTECT TRIAL OF PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY
(ISN-WCN 2026)
- No abstract available
Biomarker • Clinical • Late-breaking abstract • P3 data • Glomerulonephritis • IgA Nephropathy • Renal Disease
December 31, 2025
Single-cell spatial transcriptomics reveals potential molecular mechanisms of Abelmoschus manihot (L.) medic in treating diabetic kidney disease.
(PubMed, Imeta)
- "manihot), in the form of Huangkui capsule (HKC), combined with irbesartan (IRB) is an effective therapy for patients with diabetic kidney disease (DKD)...Following genome-wide gene screening and molecular docking simulation, we have identified the key renal receptors (Itga3, Itga5, Tgfbr1, etc.) and regulators (Jun, Junb, Stat1, etc.) underlying the therapeutic action of TFA in DKD. This study provides novel insights into the pharmaceutical mechanisms of A. manihot in the treatment of DKD."
Journal • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus • ITGA3 • ITGA5 • JUNB • STAT1 • TGFBR1
December 23, 2025
Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated Focal Segmental Glomerulosclerosis Enrolled in the DUPLEX Trial.
(PubMed, Clin J Am Soc Nephrol)
- "These findings support sparsentan's antiproteinuric benefit in patients with gFSGS, a subgroup that is often resistant to other therapeutic interventions."
Journal • Focal Segmental Glomerulosclerosis • Glomerulonephritis • Renal Disease
December 22, 2025
Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy.
(PubMed, Clin J Am Soc Nephrol)
- P3 | "Participants in PROTECT who achieved CR36 or CR110 showed greater eGFR preservation, fewer kidney failure events, and similar safety profiles compared to non-CR participants. These data reinforce recommendations to maintain proteinuria levels ideally <0.3 g/day and underscore its relationship with kidney function preservation."
Clinical • Journal • P3 data • Cardiovascular • Glomerulonephritis • Hypertension • Hypotension • IgA Nephropathy • Renal Disease
December 21, 2025
Phthalates and pharmaceuticals in soil, groundwater, and surface water downgradient of a wastewater soil infiltration system.
(PubMed, J Hazard Mater)
- "Substantial reductions were observed for caffeine (>99 %), carbamazepine (>96 %), losartan (>99 %), and phthalates (51 ± 72 % and 92 ± 5 %), with the higher attenuation for phthalates comparable to conventional activated sludge treatment...Several pharmaceuticals, including metoprolol, irbesartan, and metformin, were detected in soil samples, though it is unclear whether they were sorbed to the soil matrix or present in porewater. In downgradient surface water, diclofenac and ibuprofen exceeded risk quotient thresholds, while oxazepam surpassed the lowest predicted no-effect concentration (PNEC) in one sample, indicating ecological risks. Overall, the findings highlight both the strengths and limitations of soil infiltration systems in mitigating micropollutant contamination, emphasizing the importance of vadose zone processes while underscoring uncertainties in sorption and degradation mechanisms."
Journal
December 20, 2025
Pooled randomised QUARTET trials assessing effectiveness of a single pill for hypertension.
(PubMed, Open Heart)
- "This prospective individual participant data pooled analysis provides further evidence that the quadpill strategy is superior to initial monotherapy by virtue of improved BP-lowering, less need for uptitration and being associated with less treatment inertia."
Clinical • Journal • Cardiovascular • Hypertension
December 15, 2025
Randomized controlled clinical trial of Shenzhuo Formula in the treatment of macroalbuminuria in diabetic kidney disease and its inflammation-modulating mechanisms.
(PubMed, Precis Clin Med)
- "In a randomized, double-blind, double-dummy, active-controlled, multicenter trial, irbesartan (IRB) was the control...SZF matched IRB in proteinuria reduction but was superior in preserving renal function and improving traditional Chinese medicine symptoms in DKD, with good safety. Benefits may involve suppression of CX3CL1/MCP-1-mediated inflammation."
Clinical • Journal • Diabetic Nephropathy • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease • CX3CL1
December 15, 2025
Qingyu formula inhibits ferroptosis in HK-2 cells and in a diabetic nephropathy mouse model via the Nrf2/SLC7A11/GPX4 pathway.
(PubMed, Tissue Cell)
- "Qingyu formula protects against high glucose-induced renal injury by suppressing ferroptosis via the activation of the Nrf2/SLC7A11/GPX4 pathway. These findings support QYF as a promising candidate for targeting ferroptosis in DKD. Future studies should identify its active constituents and evaluate its efficacy in clinical trials."
Journal • Preclinical • Diabetes • Diabetic Nephropathy • Nephrology • Renal Disease • GPX4 • SLC7A11
December 11, 2025
Decoding the Neuroprotective Intervention of Angiotensin Receptor Blockers: A Multimodal Approach Using In Silico Network Pharmacology, Molecular Modeling, and In Vivo Validation of Key Markers.
(PubMed, ACS Chem Neurosci)
- "Building on these findings, this study sought to compare the activity of azilsartan with other commonly used ARBs, including telmisartan, olmesartan, valsartan, eprosartan, irbesartan, and candesartan, using an integrative network pharmacology approach. To experimentally validate these predictions, in vivo studies were conducted in a scopolamine-induced memory-impaired model, which demonstrated significant restoration of the levels of AKT1 and PIK3CA. These findings clearly demonstrate the PI3K/AKT modulating effects of azilsartan, reinforcing its repurposing potential in dementia and related disorders, thereby expanding novel therapeutic opportunities within this drug class."
Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Dementia • AKT1 • PIK3CA • PIK3CB
December 06, 2025
A systematic review of commencing full dose antihypertensives in newly diagnosed hypertension.
(PubMed, Blood Press)
- "The review assessed commonly used antihypertensive drugs (perindopril 8 mg, ramipril 10 mg, amlodipine 10 mg, losartan 100 mg, irbesartan 300 mg, candesartan 16 mg and candesartan 32 mg) compared to low starting doses or placebo RCTs. The review indicates that initiating full dose antihypertensives for essential hypertension may be beneficial and safe. The available data are limited and further RCTs are required to assess this in specific patient groups to assess safety and efficacy."
Journal • Review • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Hypertension • Nephrology • Renal Disease
December 09, 2025
Pharmacogenomics-Guided Precision Therapy for Chronic Kidney Disease with Resistant Hypertension: A Prospective Cohort Study.
(PubMed, Kidney Blood Press Res)
- "PGx-guided precision therapy facilitates rapid BP control, reduces polypharmacy and adverse events, and delays kidney function decline in CKD patients with RH. This study, the first PGx clinical trial targeting a multi-ethnic population in Northwest China, offers valuable insights into personalized treatment approaches for CKD with RH in East Asia."
Biomarker • Journal • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease
December 05, 2025
Post-translational switch of DHCR24 acetylation sustains sterol synthesis and promotes HCC via the 7-ketocholesterol/p62 axis.
(PubMed, Cell Rep)
- "Pharmacologic inhibition of DHCR24 expression and acetylation with the US Food and Drug Administration (FDA)-approved drug irbesartan suppresses cell proliferation and reduces tumor burden in xenograft and carcinogen-induced mouse models. Reduced p62 expression parallels the antitumor effects. These findings define DHCR24 acetylation as a metabolic switch linking sterol synthesis to oncogenesis and highlight the DHCR24-7-ketocholesterol-p62 axis as a therapeutic target for HCC."
Journal • Hepatocellular Cancer • Oncology • Solid Tumor
December 03, 2025
Primary aldosteronism: pharmacotherapy vs surgery vs embolization efficacy - systematic review and network meta-analysis of studies predominantly conducted in China.
(PubMed, Front Endocrinol (Lausanne))
- "Among pharmacological treatments, mineralocorticoid receptor antagonists and irbesartan (MRAs+IRB) had the greatest antihypertensive effect (SBP: WMD = -18.90, 95% Crl -29.20 to -8.55; DBP: WMD = -22.14, 95% Crl -31.81 to -12.50)...This study showed TADR + RND and MRAs + IRB had best efficacy in surgical and pharmacological treatments, respectively, but 76% of the included studies were conducted in China, which may affect the generalizability of the findings. Therefore, the results need further validation."
Clinical • Journal • Retrospective data • Review • Cardiovascular • Endocrine Disorders • Hypertension
November 27, 2025
Angiotensin II Activates Yes-Associated Protein (YAP) in Fibroblast Promoting Deep Fascia Remodeling.
(PubMed, Int J Mol Sci)
- "This gene expression was decreased by pretreatment with the AT1R antagonist irbesartan or the YAP inhibitor verteporfin. These findings show that Ang II acts as both a biochemical and biomechanical signal in the deep fascia, activating YAP signaling and promoting fibrotic remodeling. Our results uncover a new Ang II-YAP pathway in fascial fibroblasts, offering potential targets for therapy in fibrosis and related conditions involving the deep fascia."
Journal • Fibrosis • Immunology • Pain • COL1A1 • COL3A1
November 26, 2025
Adherence, Switches, and Drug Spending After Angiotensin Receptor Blocker Recalls and Shortages.
(PubMed, JAMA Health Forum)
- "From 2018 to 2019, hundreds of valsartan, losartan, and irbesartan products were recalled due to ingredient impurities. This cohort study shows that access to alternatives may have mitigated gaps in treatment during the 2018 to 2019 ARB recalls and drug shortages. Potential disparate impacts among certain subgroups highlight the need for policies to mitigate financial and other systematic access barriers to receiving health care during drug shortages."
Journal • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Heart Failure • Hypertension • Nephrology • Renal Disease
November 20, 2025
Matching-adjusted indirect comparison of kidney function in patients with immunoglobulin A nephropathy treated with nefecon or sparsentan.
(PubMed, J Comp Eff Res)
- P3 | "Aim: We compared the effects of nefecon, an oral targeted-release budesonide formulation, and sparsentan, an oral, dual endothelin-angiotensin receptor antagonist, on estimated glomerular filtration rate (eGFR) in patients with immunoglobulin A nephropathy, a leading cause of chronic kidney disease. Materials & We conducted an anchored matching-adjusted indirect comparison (MAIC) using patient-level data from NefIgArd (NCT03643965; n = 364), a randomized (1:1) trial of nefecon plus optimized renin-angiotensin system inhibitor (RASi) therapy versus placebo plus RASi; and aggregate data from PROTECT (NCT03762850; n = 404), a randomized (1:1) trial of sparsentan versus irbesartan, an angiotensin receptor blocker...Sensitivity analysis results were consistent with the main findings. In patients with immunoglobulin A nephropathy, nefecon plus optimized RASi may preserve kidney function to a greater extent than sparsentan."
Journal • Chronic Kidney Disease • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease
October 18, 2025
A Case Report of Fabry Disease Combined with IgAN
(KIDNEY WEEK 2025)
- "After six months of ERT(enzyme replacement therapy), irbesartan and hydroxychloroquine sulfate treatment, the urine protein of the patient turned negative. It is vital to improve the detection rate of the disease by combining family history, clinical manifestations, α-Gal A activity, and genetic testing. Kidney biopsy specimens in the patient."
Case report • Clinical • Fabry Disease • Genetic Disorders • Glomerulonephritis • IgA Nephropathy • Renal Disease
October 18, 2025
IgAN with Orthostatic Proteinuria: A Case Report
(KIDNEY WEEK 2025)
- "Over this period, due to poorly controlled proteinuria, he had been given various treatment regimens on top of RASi support therapy, including steroids, Tacrolimus, leflunomide, hydroxychloroquine, mycophenolate mofetil, ambrisentan, and Tripterygium wilfordii polyglycoside, but his spot urine protein levels remained unsatisfactory...We thus considered that the patient had IgAN coexisting with orthostatic proteinuria and withdrew immunosuppressive medications, retaining only irbesartan at 150 mg/day...This case underscores the importance of considering this diagnosis in adult IgAN patients with discordant findings or poor response to treatment. Routine use of split urine collections, especially in patients with variable home test results, can help avoid misdiagnosis and overtreatment."
Case report • Clinical • Glomerulonephritis • IgA Nephropathy • Ophthalmology • Renal Disease
October 18, 2025
Rituximab (RTX): Not Only Effective in Anti-Phospholipase A2 Receptor (PLA2R)-Associated Membranous Nephropathy (MN)
(KIDNEY WEEK 2025)
- "Case Description 66 years old man with history of T-cell lymphoblastic lymphoma status post allogenic HSCT 2 years before presentation, complicated by chronic GVHD with skin and liver involvement, chronically on ruxolitinib and briefly on belumosudil, presented with acute onset lower extremity edema, proteinuria 7600 mg in 24 hours, serum albumin 2.1 g/dL, serum creatinine 1.3 mg/dL (base 1.1)...Irbesartan started, apixaban for DVT prophylaxis, atorvastatin and evolocumab for dyslipidemia...Clinically doing excellent in complete remission, remains on irbesartan, dapagliflozin, atorvastatin, and evolocumab. Discussion Treatment of MN post allogenic HSCT is based on case report and case series, and different agents have been used including calcineurin inhibitors, mycophenolate mofetil, cyclophosphamide, and more recently rituximab...The lack of serological markers (i.e. antiPLA2R antibody) made the decision to continue with RTX and not changing to a different agent..."
Bone Marrow Transplantation • Chronic Graft versus Host Disease • Dyslipidemia • Glomerulonephritis • Graft versus Host Disease • Hematological Malignancies • Immunology • Lymphoma • Metabolic Disorders • Renal Disease
October 18, 2025
Primary Hyperaldosteronism Presenting Clinically as Classic Pheochromocytoma
(KIDNEY WEEK 2025)
- "Therapy at the time included irbesartan 300mg daily, nebivolol 20mg daily, amlodipine 10mg daily and hydralazine 10mg three times daily. Symptoms of profuse sweating, palpitations and impending sense of doom are often associated with pheochromocytomas which can also result in hypertension. This case demonstrates how variability can exist in symptomatic burden."
Clinical • Cardiovascular • Endocrine Disorders • Hypertension • Solid Tumor
1 to 25
Of
779
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32